Ashish Manne· @AshishManne · X·· 2026-04-20Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
daraxonrasib ± GnP · mono ORR 47%; +GnP ORR 55%, DCR 90%
Body
Excited to present our posters at #AACR26.
From plasma cfDNA methylation to MUC5AC-driven immune biology, our work aims to better understand prognosis and resistance in pancreatic cancer.
#PancreaticCancer #Immunotherapy #PrecisionOncology
@OhioStateMedOnc
@OSUCCC_James
Heat 9 · 6 likes · 1 reply · 2 reposts
Source: Ashish Manne · x.com